RA’ANANA, Israel & NEW YORK–(BUSINESS WIRE)–Nov. 6, 2018– UroGen Pharma Ltd. (Nasdaq:URGN), today announced that management will present at two investor conferences in November 2018:
- Stifel 2018 Healthcare Conference
- Tuesday, November 13
- 9:30AM Eastern Time
- New York, NY
- Jefferies 2018 London Healthcare Conference
- Thursday, November 15
- 9:20AM Greenwich Mean Time
- London, UK
A live audio webcast of each event will be available on the Investors section of UroGen’s website, www.urogen.com. A replay of each webcast will be available on the website for approximately two weeks.
About UroGen Pharma Ltd.
UroGen Pharma Ltd. (Nasdaq:URGN) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. UroGen has developed RTGel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s lead product candidates, UGN-101 and UGN-102, are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. UroGen is headquartered New York, NY with offices in Ra’anana, Israel and Los Angeles, CA.
Source: UroGen Pharma Ltd.
UroGen Pharma Ltd.
Kate Bechtold, 914-552-0456
Director, Corporate Communications & Investor Relations